| BRCA1, pathology, and survival |
| HT Lynch and P Watson |
|
JCO Feb 1 1998: 395–396.
[PDF]
|
 |
|
Survival of BRCA1 breast and ovarian cancer patients: a population- based study from southern Sweden |
| |
OT Johannsson, J Ranstam, A Borg, and H Olsson |
| |
JCO Feb 1 1998: 397–404.
[Abstract]
[PDF]
|
|
|
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study |
| |
PG Rose, JA Blessing, AR Mayer, and HD Homesley |
| |
JCO Feb 1 1998: 405–410.
[Abstract]
[PDF]
|
|
|
Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial |
| |
C Grimaldi, H Bleiberg, F Gay, M Messner, P Rougier, TC Kok, L Cirera, A Cervantes, J De Greve, B Paillot, M Buset, D Nitti, T Sahmoud, N Duez, and J Wils |
| |
JCO Feb 1 1998: 411–417.
[Abstract]
[PDF]
|
|
|
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer |
| |
CH Kohne, P Schoffski, H Wilke, C Kaufer, R Andreesen, U Ohl, U Klaasen, M Westerhausen, W Hiddemann, G Schott, A Harstick, J Bade, A Horster, U Schubert, H Hecker, B Dorken, and HJ Schmoll |
| |
JCO Feb 1 1998: 418–426.
[Abstract]
[PDF]
|
|
|
Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator |
| |
OA Ogunbiyi, PJ Goodfellow, K Herfarth, G Gagliardi, PE Swanson, EH Birnbaum, TE Read, JW Fleshman, IJ Kodner, and JF Moley |
| |
JCO Feb 1 1998: 427–433.
[Abstract]
[PDF]
|
|
|
Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer |
| |
B Glimelius, T Linne, K Hoffman, L Larsson, JH Svensson, P Nasman, B Svensson, and C Helmers |
| |
JCO Feb 1 1998: 434–440.
[Abstract]
[PDF]
|
|
|
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17 |
| |
B Fisher, J Dignam, N Wolmark, E Mamounas, J Costantino, W Poller, ER Fisher, DL Wickerham, M Deutsch, R Margolese, N Dimitrov, and M Kavanah |
| |
JCO Feb 1 1998: 441–452.
[Abstract]
[PDF]
|
|
|
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate |
| |
P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, W Bezwoda, G Gardin, A Gudgeon, M Morgan, A Fornasiero, W Hoffmann, J Michel, T Hatschek, T Tjabbes, HA Chaudri, U Hornberger, and PF Trunet |
| |
JCO Feb 1 1998: 453–461.
[Abstract]
[PDF]
|
|
|
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers |
| |
S Sjogren, M Inganas, A Lindgren, L Holmberg, and J Bergh |
| |
JCO Feb 1 1998: 462–469.
[Abstract]
[PDF]
|
|
|
p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer |
| |
PC Clahsen, CJ van de Velde, C Duval, C Pallud, AM Mandard, A Delobelle- Deroide, L van den Broek, TM Sahmoud, and MJ van de Vijver |
| |
JCO Feb 1 1998: 470–479.
[Abstract]
[PDF]
|
|
|
Skin recurrences after breast-conserving therapy for early-stage breast cancer |
| |
I Gage, SJ Schnitt, A Recht, A Abner, S Come, LN Shulman, JM Monson, B Silver, JR Harris, and JL Connolly |
| |
JCO Feb 1 1998: 480–486.
[Abstract]
[PDF]
|
|
|
Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls |
| |
M Dorval, E Maunsell, L Deschenes, J Brisson, and B Masse |
| |
JCO Feb 1 1998: 487–494.
[Abstract]
[PDF]
|
|
|
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors |
| |
DL Barton, CL Loprinzi, SK Quella, JA Sloan, MH Veeder, JR Egner, P Fidler, PJ Stella, DK Swan, NL Vaught, and P Novotny |
| |
JCO Feb 1 1998: 495–500.
[Abstract]
[PDF]
|
|
|
Life after breast cancer: understanding women's health-related quality of life and sexual functioning |
| |
PA Ganz, JH Rowland, K Desmond, BE Meyerowitz, and GE Wyatt |
| |
JCO Feb 1 1998: 501–514.
[Abstract]
[PDF]
|
|
|
Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy |
| |
PM Ravdin, IA Siminoff, and JA Harvey |
| |
JCO Feb 1 1998: 515–521.
[Abstract]
[PDF]
|
|
|
Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study |
| |
J Laver, M Amylon, S Desai, M Link, M Schwenn, H Mahmoud, and J Shuster |
| |
JCO Feb 1 1998: 522–526.
[Abstract]
[PDF]
|
|
|
Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group |
| |
FM Uckun, MG Sensel, HN Sather, PS Gaynon, DC Arthur, BJ Lange, PG Steinherz, P Kraft, R Hutchinson, JB Nachman, GH Reaman, and NA Heerema |
| |
JCO Feb 1 1998: 527–535.
[Abstract]
[PDF]
|
|
|
Second cancers following pediatric Hodgkin's disease |
| |
SL Wolden, KR Lamborn, SF Cleary, DJ Tate, and SS Donaldson |
| |
JCO Feb 1 1998: 536–544.
[Abstract]
[PDF]
|
|
|
Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia |
| |
K Nysom, K Holm, SR Lipsitz, SM Mone, SD Colan, EJ Orav, SE Sallan, JH Olsen, H Hertz, JR Jacobsen, and SE Lipshultz |
| |
JCO Feb 1 1998: 545–550.
[Abstract]
[PDF]
|
|
|
Error rates in clinical radiotherapy |
| |
RM Macklis, T Meier, and MS Weinhous |
| |
JCO Feb 1 1998: 551–556.
[Abstract]
[PDF]
|
|
|
Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated |
| |
I Funke and W Schraut |
| |
JCO Feb 1 1998: 557–566.
[Abstract]
[PDF]
|
|
|
Telomerase activity in pleural effusions: diagnostic significance |
| |
CT Yang, MH Lee, RS Lan, and JK Chen |
| |
JCO Feb 1 1998: 567–573.
[Abstract]
[PDF]
|
|
|
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246 |
| |
OW Press, M LeBlanc, TJ O'Rourke, S Gagnet, RA Chapman, SP Balcerzak, and RI Fisher |
| |
JCO Feb 1 1998: 574–578.
[Abstract]
[PDF]
|
|
|
Phase II trial of fludarabine monophosphate in patients with mantle- cell lymphomas |
| |
D Decaudin, J Bosq, G Tertian, G Nedellec, A Bennaceur, AM Venuat, C Bayle, P Carde, B Bendahmane, M Hayat, and JN Munck |
| |
JCO Feb 1 1998: 579–583.
[Abstract]
[PDF]
|
|
|
Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant |
| |
R Little, RE Wittes, DL Longo, and WH Wilson |
| |
JCO Feb 1 1998: 584–588.
[Abstract]
[PDF]
|
|
|
Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study |
| |
EH Kraut, JJ Crowley, JL Wade, LR Laufman, M Alsina, SA Taylor, and SE Salmon |
| |
JCO Feb 1 1998: 589–592.
[Abstract]
[PDF]
|
|
|
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group |
| |
JR Berenson, A Lichtenstein, L Porter, MA Dimopoulos, R Bordoni, S George, A Lipton, A Keller, O Ballester, M Kovacs, H Blacklock, R Bell, JF Simeone, DJ Reitsma, M Heffernan, J Seaman, and RD Knight |
| |
JCO Feb 1 1998: 593–602.
[Abstract]
[PDF]
|
|
|
18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow |
| |
F Moog, M Bangerter, J Kotzerke, A Guhlmann, N Frickhofen, and SN Reske |
| |
JCO Feb 1 1998: 603–609.
[Abstract]
[PDF]
|
|
|
Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants |
| |
MJ Egorin, DM Rosen, R Sridhara, L Sensenbrenner, and M Cottler-Fox |
| |
JCO Feb 1 1998: 610–615.
[Abstract]
[PDF]
|
|
|
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide |
| |
MP Goren, LB Anthony, KR Hande, DH Johnson, WP Brade, MW Frazier, DA Bush, and JT Li |
| |
JCO Feb 1 1998: 616–621.
[Abstract]
[PDF]
|
|
|
Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial |
| |
W Eberhardt, H Wilke, G Stamatis, M Stuschke, A Harstrick, H Menker, B Krause, MR Mueller, M Stahl, M Flasshove, V Budach, D Greschuchna, N Konietzko, H Sack, and S Seeber |
| |
JCO Feb 1 1998: 622–634.
[Abstract]
[PDF]
|
|
|
Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer |
| |
LL Herscher, SM Hahn, G Kroog, H Pass, B Temeck, B Goldspiel, J Cook, JB Mitchell, and J Liebmann |
| |
JCO Feb 1 1998: 635–641.
[Abstract]
[PDF]
|
|
|
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients |
| |
WP Steward, J von Pawel, U Gatzemeier, P Woll, N Thatcher, G Koschel, L Clancy, J Verweij, R de Wit, W Pfeifer, J Fennelly, M von Eiff, and J Frisch |
| |
JCO Feb 1 1998: 642–650.
[Abstract]
[PDF]
|
|
|
Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database |
| |
S Ramalingam, K Pawlish, S Gadgeel, R Demers, and GP Kalemkerian |
| |
JCO Feb 1 1998: 651–657.
[Abstract]
[PDF]
|
|
|
Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin |
| |
G Bacci, S Ferrari, N Delepine, F Bertoni, P Picci, M Mercuri, P Bacchini, A Brach del Prever, A Tienghi, A Comandone, and M Campanacci |
| |
JCO Feb 1 1998: 658–663.
[Abstract]
[PDF]
|
|
|
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study |
| |
KA Margolin, PY Liu, LE Flaherty, JA Sosman, MJ Walker, JW Smith, 3rd, WS Fletcher, GR Weiss, JM Unger, and VK Sondak |
| |
JCO Feb 1 1998: 664–669.
[Abstract]
[PDF]
|
|
|
Molecular genetics of familial cutaneous melanoma |
| |
FG Haluska and FS Hodi |
| |
JCO Feb 1 1998: 670–682.
[Abstract]
[PDF]
|
|
|
Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group |
| |
S Stewart, H Jablonowski, FD Goebel, K Arasteh, M Spittle, A Rios, D Aboulafia, J Galleshaw, and BJ Dezube |
| |
JCO Feb 1 1998: 683–691.
[Abstract]
[PDF]
|
|
|
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study |
| |
SB Kaye, GM Mead, S Fossa, M Cullen, R deWit, I Bodrogi, C van Groeningen, R Sylvester, L Collette, S Stenning, L De Prijck, E Lallemand, and P deMulder |
| |
JCO Feb 1 1998: 692–701.
[Abstract]
[PDF]
|
|
|
Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience |
| |
SB Saxman, D Finch, R Gonin, and LH Einhorn |
| |
JCO Feb 1 1998: 702–706.
[Abstract]
[PDF]
|
|
|
Metastatic germ cell tumors: modeling for response to chemotherapy |
| |
DF Bajorin, M Mazumdar, M Meyers, RJ Motzer, V Vlamis, P Lin, and GJ Bosl |
| |
JCO Feb 1 1998: 707–715.
[Abstract]
[PDF]
|
|
|
Filgrastim during combination chemotherapy of patients with poor- prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom |
| |
SD Fossa, SB Kaye, GM Mead, M Cullen, R de Wit, I Bodrogi, CJ van Groeningen, PH De Mulder, S Stenning, E Lallemand, L De Prijck, and L Collette |
| |
JCO Feb 1 1998: 716–724.
[Abstract]
[PDF]
|
|
|
Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy |
| |
K Fizazi, S Culine, JP Droz, A Kramar, C Theodore, P Ruffie, and T Le Chevalier |
| |
JCO Feb 1 1998: 725–732.
[Abstract]
[PDF]
|
|
|
Paternity in men with stage I testis tumors on surveillance |
| |
HW Herr, N Bar-Chama, M O'Sullivan, and PC Sogani |
| |
JCO Feb 1 1998: 733–734.
[Abstract]
[PDF]
|
|
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck |
| |
B Brockstein, DJ Haraf, K Stenson, A Fasanmade, R Stupp, B Glisson, SM Lippman, MJ Ratain, L Sulzen, A Klepsch, RR Weichselbaum, and EE Vokes |
| |
JCO Feb 1 1998: 735–744.
[Abstract]
[PDF]
|
|
|
Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients |
| |
N Siegelmann-Danieli, A Hanlon, JA Ridge, R Padmore, DA Fein, and CJ Langer |
| |
JCO Feb 1 1998: 745–753.
[Abstract]
[PDF]
|
|
|
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study |
| |
EA Perez, P Hesketh, J Sandbach, J Reeves, S Chawla, M Markman, J Hainsworth, W Bushnell, and C Friedman |
| |
JCO Feb 1 1998: 754–760.
[Abstract]
[PDF]
|
|
|
Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model |
| |
JS Groeger, S Lemeshow, K Price, DM Nierman, P White, Jr, J Klar, S Granovsky, D Horak, and SK Kish |
| |
JCO Feb 1 1998: 761–770.
[Abstract]
[PDF]
|
|
|
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center |
| |
MJ Nolte, R Berkery, B Pizzo, L Baltzer, D Grossano, CD Lucarelli, and MG Kris |
| |
JCO Feb 1 1998: 771–778.
[Abstract]
[PDF]
|
|
|
Does tamoxifen cause cancer in humans? |
| |
V Stearns and EP Gelmann |
| |
JCO Feb 1 1998: 779–792.
[Abstract]
[PDF]
|
|
|
1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology |
| |
|
| |
JCO Feb 1 1998: 793–795.
[Abstract]
[PDF]
|
|
| Carcinoid syndrome |
| E Galanis, LK Kvols, and J Rubin |
|
JCO Feb 1 1998: 796–798.
[PDF]
|
|
| Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity |
| E Cvitkovic |
|
JCO Feb 1 1998: 799–800.
[PDF]
|
|
| High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America |
| M Crump, S Gluck, K Pritchard, L Shepherd, and J Pater |
|
JCO Feb 1 1998: 800–802.
[PDF]
|
|
| Is concomitant radiotherapy and chemotherapy superior to optimal radiotherapy alone in anal cancer? |
| M Bhattacharyya and R Sarin |
|
JCO Feb 1 1998: 802–803.
[PDF]
|
|
| Analgesic effects of chemotherapy? |
| A Caraceni and F De Conno |
|
JCO Feb 1 1998: 803a.
[PDF]
|
|
| Clinical benefit as a primary efficacy endpoint |
| E Ballatori, A Del Favero, and F Roila |
|
JCO Feb 1 1998: 803b–804.
[PDF]
|
|
| Second bone marrow transplantation in non-Hodgkin's lymphoma |
| A Messori, M Costantini, L Bonistalli, and R Alterini |
|
JCO Feb 1 1998: 804–806.
[PDF]
|
|
| Reverse transcriptase-polymerase chain reaction and islet cell carcinoma: not antagonist, but complementary tools |
| J Benhattar, L Perey, R Peters, and S Leyvraz |
|
JCO Feb 1 1998: 806–807.
[PDF]
|
|
| Combined modality therapy for lung cancer |
| RJ Baglan |
|
JCO Feb 1 1998: 807–808.
[PDF]
|
|
| Hand-foot syndrome in sickle cell disease |
| F Rosner |
|
JCO Feb 1 1998: 808–809.
[PDF]
|
|
| Third-party payers and breast cancer study |
| EG de Vries, PJ Meijs, and S Rodenhuis |
|
JCO Feb 1 1998: 809.
[PDF]
|
|
| Standard versus high-dose therapy in 10+ breast cancer |
| Y Nieto, PJ Cagnoni, and RB Jones |
|
JCO Feb 1 1998: 810–811.
[PDF]
|
|
| Doxil in breast cancer |
| FM Muggia |
|
JCO Feb 1 1998: 811–812.
[PDF]
|
|
| Anaphylactoid reaction in a normal donor given granulocyte colony- stimulating factor |
| DR Adkins |
|
JCO Feb 1 1998: 812–813.
[PDF]
|
|
